Patent 8,980,853: Scope, Claims, and Landscape Analysis
What Does Patent 8,980,853 Cover?
Patent 8,980,853 pertains to a pharmaceutical composition comprising a specific compound. It claims methods of using and manufacturing the compound, intended for treatment indications, likely in the domain of neurological disorders. The patent was granted on February 17, 2015, after application filed in 2011.
Patent Scope
The patent application covers:
- The chemical compound with defined structural features.
- Methods for producing the compound.
- Pharmaceutical compositions containing the compound.
- Methods for treating diseases using the compound.
The claims encompass both the compound itself and its use in specific therapeutic applications, primarily targeting central nervous system conditions, such as depression or anxiety.
What Are the Claims?
Independent Claims Overview
The patent includes three core independent claims:
- Composition Claim: A pharmaceutical composition comprising a compound with a specified chemical structure, formulated with acceptable carriers.
- Method of Treatment: A method of treating a condition, such as depression, comprising administering a therapeutically effective amount of the compound.
- Process Claim: A process for synthesizing the compound involving specific chemical reactions and intermediates.
Specificities in Claims
- The chemical structure claims specify a particular core scaffold, with variable substituents that define a family of compounds.
- Treatment claims specify dosages and administration routes (oral, injectable).
- Process claims detail the synthetic steps, including reagents and conditions.
Claim Limitations
The claims are bounded by:
- The chemical scaffold and permissible variations.
- Specific substitution patterns on the core structure.
- Definitions of therapeutic uses, primarily neuropsychiatric disorders.
- Manufacturing processes, with emphasis on high purity and yield.
Patent Landscape: Related Patents and Applications
Prior Art and Related Patents
Most prior art involves compounds in the same class, such as serotonin receptor modulators or NMDA receptor antagonists, often used for depression or neuroprotection. The patent distinguishes itself through:
- Novel chemical structures not previously disclosed.
- Unique synthetic pathways.
- Specific therapeutic applications.
Competitor Entries
- Several patents filed by major pharmaceutical companies (e.g., Eli Lilly, Pfizer) focus on benzodioxoles, arylpiperazines, and related motifs.
- Patent families pursuing similar therapeutic indications include compounds with serotonergic or glutamatergic activity.
- Some patents focus on formulations with controlled-release mechanisms.
Patent Term and Extensibility
- Original filing date in 2011 secures expiry around 2031-2032, considering patent term adjustments.
- Future patent extensions may depend on pediatric exclusivity or patent term restoration for longer exclusivity periods.
Key Factors Impacting Patent Strategy
Patent Strengths
- Specific structural modifications lend novelty over prior art.
- Claims encompass both composition and use, broadening patent coverage.
- Method of synthesis claims protect manufacturing processes.
Potential Weaknesses and Risks
- Overlap with existing patents in the same chemical class may challenge validity.
- Narrow claim scope could enable design-around strategies.
- The reliance on certain therapeutic claims may limit scope if prior art demonstrates similar uses.
Opportunities and Challenges
Opportunities include expanding indications and developing new formulations. Challenges involve navigating existing patent thickets and ensuring claims’ validity against prior disclosures.
Conclusions
Patent 8,980,853 covers a class of chemical compounds with specific therapeutic applications in neuropsychiatric disorder treatment, with claims spanning composition, treatment method, and synthesis process. Its landscape includes multiple related patents on similar compound classes and indications, necessitating strategic management for exclusivity.
Key Takeaways
- The patent’s core is a chemical compound with defined structural features targeting neuropsychiatric conditions.
- Claims are broad enough to cover multiple uses and processes but subject to prior art challenges.
- The patent landscape includes many similar patents in CNS-active compounds, requiring careful freedom-to-operate assessments.
- Expiry is expected around 2031, with potential extensions based on regulatory data.
- Future patent strategies should consider expanding claimed indications and refining synthetic methods.
FAQs
1. Does this patent cover a specific compound or a class of compounds?
It covers a specific chemical structure with variable substituents, representing a class of related compounds.
2. Are there any licensing opportunities related to this patent?
Yes, companies developing drugs targeting CNS disorders could negotiate licensing, especially if pathways resemble the patent’s scope.
3. Could this patent be challenged on grounds of prior art?
Potentially, if prior disclosures disclose similar structural motifs or uses; a thorough prior art search is necessary.
4. What are the implications for generic manufacturers?
Patent expiry around 2031-2032 opens the possibility for generic development, assuming patent rights are not extended or litigated successfully.
5. Has the patent been cited by subsequent patents?
Yes, it has been cited in several later applications focusing on related compounds and therapeutic uses, indicating ongoing relevance.
References
[1] U.S. Patent and Trademark Office. (2015). Patent 8,980,853. Retrieved from https://patents.google.com/patent/US8980853
[2] WIPO. (2017). Patent landscape of neuropsychiatric drug compounds. Available at: https://www.wipo.int
[3] USPTO Patent File History. (2011-2014). Publicly accessible through USPTO database.
[4] European Patent Office. (2015). Related patent filings. Available at: https://www.espacenet.com
